TNYA
NASDAQTenaya Therapeutics Inc.
Price$0.78-0.00 (-0.26%)
01:30 PM07:00 PM
News · 26 weeks60+150%
2025-12-072026-05-31
Mix2790d
- Insider10(37%)
- SEC Filings8(30%)
- Other4(15%)
- Earnings4(15%)
- Offering1(4%)
Latest news
25 items- PRTenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in SymptomsAll Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA's Rare Disease Evidence Principles Process Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m. PT SOUTH SAN FRANCISCO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported promising new interim safety and efficacy data from the company's MyPEAK™-1 Phase 1b/2 clinica
- PRTenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026. Webcast Details: Tenaya Therapeutics will host a live webcast to review the new data from MyPEAK™-1 on Wednesday, June 3, 2026 at 8:00 a.m. ET. To access the live event, participa
- INSIDERSEC Form 4 filed by Director Williams R Sanders4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Walsh Jeffrey T.4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Stehman-Breen Catherine4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Srivastava Deepak4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Parschauer Karah Herdman4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Lee June4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSEC Form 4 filed by Director Burroughs Amy L.4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- SECTenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- PRTenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of its executive team will present and participate in the upcoming Jefferies Global Healthcare Conference taking place from June 2-4, 2026, in New York, New York. Faraz Ali, Tenaya's Chief Executive Officer, will provide a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET. The live webcast of the presentation may be accessed from the Investors section of Tenaya's website. An ar
- INSIDERChief Executive Officer Ali Faraz sold $2,690 worth of shares (3,390 units at $0.79), decreasing direct ownership by 0.76% to 440,014 units (SEC Form 4) (tax withholding)4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERChief Medical Officer Tingley Whittemore sold $2,477 worth of shares (3,121 units at $0.79), decreasing direct ownership by 1% to 215,497 units (SEC Form 4) to cover taxes4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- INSIDERSVP, Finance Higa Tomohiro sold $1,178 worth of shares (1,485 units at $0.79), decreasing direct ownership by 1% to 118,267 units (SEC Form 4) to cover taxes4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
- PRPositive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVCAll Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of TN-401 Activity in Heart Muscle Cells PRIME Designation Granted by European Medicines Agency Tenaya Management to Host a Webcast Conference Call to Review Results on Friday, May 15 at 10:30 a.m. ET / 7:30 a.m. PT Following Late-Breaker Presentation at ASGCT 2026 SOUTH SAN FRANCISCO, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curativ
- SECSEC Form 10-Q filed by Tenaya Therapeutics Inc.10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- SECTenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- PRTenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateOne-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM Expected in the Second Quarter 2026 Preclinical Data at MDA 2026 Highlighted TN-301's Activity in Duchenne Muscular Dystrophy Disease Models; Distinct Mechanism of HDAC6 Inhibition Supportive of TN-301's Potential in Multiple Indications Entered Research Collaboration with Alnylam to Identify and Validate Genetic Targets for Cardiovascular Conditions SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc.
- PRTenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya's Work with Patients to Advance Gene Therapy and Early-Stage Pipeline Innovations in Cardiac Gene Editing SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the acceptance of multiple abstracts for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annu
- SECSEC Form DEFA14A filed by Tenaya Therapeutics Inc.DEFA14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- SECSEC Form DEF 14A filed by Tenaya Therapeutics Inc.DEF 14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- SECSEC Form 10-K filed by Tenaya Therapeutics Inc.10-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- SECTenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
- PRTenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateReported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports TN-301's Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discove
- PRTenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular DystrophyTenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301's Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
TNYA FAQ
7 questionsWhat does Tenaya Therapeutics Inc. do?
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.Where does TNYA stock trade?
Tenaya Therapeutics Inc. (TNYA) is listed on NASDAQ.What sector and industry is TNYA in?
Tenaya Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tenaya Therapeutics Inc. go public?
Tenaya Therapeutics Inc. (TNYA) completed its IPO in 2021.What are analysts saying about TNYA?
Tenaya Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2024-06-10.What companies are similar to TNYA?
Notable peers in the same industry include ELYM (Eliem Therapeutics Inc), SGTX (Sigilon Therapeutics Inc.), TPST (Tempest Therapeutics Inc.). Compare TNYA side-by-side with any of them on Quantisnow.How can I track TNYA on Quantisnow?
Quantisnow aggregates Tenaya Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TNYA to receive live email and push alerts on every new disclosure.